Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Descriptor ID |
D003550
|
| MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
| Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 | | 1996 | 4 | 1 | 5 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 3 | 1 | 4 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 2 | 7 | | 2002 | 12 | 0 | 12 | | 2003 | 8 | 0 | 8 | | 2004 | 13 | 0 | 13 | | 2005 | 15 | 4 | 19 | | 2006 | 13 | 3 | 16 | | 2007 | 22 | 2 | 24 | | 2008 | 13 | 3 | 16 | | 2009 | 18 | 1 | 19 | | 2010 | 21 | 3 | 24 | | 2011 | 15 | 1 | 16 | | 2012 | 19 | 1 | 20 | | 2013 | 3 | 2 | 5 | | 2014 | 21 | 3 | 24 | | 2015 | 26 | 0 | 26 | | 2016 | 29 | 1 | 30 | | 2017 | 25 | 1 | 26 | | 2018 | 30 | 4 | 34 | | 2019 | 37 | 2 | 39 | | 2020 | 44 | 1 | 45 | | 2021 | 52 | 2 | 54 | | 2022 | 53 | 0 | 53 | | 2023 | 59 | 0 | 59 | | 2024 | 36 | 4 | 40 | | 2025 | 28 | 0 | 28 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. Ann Am Thorac Soc. 2025 Nov; 22(11):1696-1708.
-
Apablaza T, Barros-Poblete M, Delpiano L, Villanueva S, Guequen A, Tapia-Balladares B, Haq I, Tribiños F, Hernández-Rivas S, Verdon B, Biggart MGS, Sánchez Y, Ward C, Baxter BD, Restrepo D, Cornejo I, Tarran R, Catalán MA, Gray MA, Flores CA. Succinate Chemosensing Induces Cystic Fibrosis Transmembrane Conductance Regulator-dependent Airway Clearance that Is Impaired in Cystic Fibrosis. Am J Respir Cell Mol Biol. 2025 Nov; 73(5):769-779.
-
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children =6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct; 211(10):1915-1925.
-
Joseph RA, Haley RM, Padilla MS, Ricciardi AS, Yamagata HM, Mitchell MJ. Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair. Nano Lett. 2025 Oct 01; 25(39):14348-14355.
-
Scharf G, Davidson CR, Ustiyan V, Falkenberg LG, Adavalli A, Meeker JD, Morgan H, Ostmann AJ, Hudock KM, Brewington JJ, Clancy JP, Kramer EL. TGF-ß induces excessive pulmonary IL-6 secretion in cystic fibrosis via PI3K. Am J Physiol Lung Cell Mol Physiol. 2025 Oct 01; 329(4):L470-L479.
-
Hoppe JE, Vigers T, Trujillo A, Hanley E, Sagel SD, Zemanick ET. Impact of Home Collection and Shipping of Respiratory Specimens on Bacterial Pathogen Detection in Children With Cystic Fibrosis. Pediatr Pulmonol. 2025 Sep; 60(9):e71289.
-
Cheng Y, Brokamp C, Manning ER, Kramer EL, Ryan PH, Szczesniak RD, Gecili E. Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression. BMC Med Inform Decis Mak. 2025 Aug 13; 25(1):304.
-
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A. Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):2674-2684.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|